Sorafenib after Arterial Chemoembolization in Child-Pugh A and B Cirrhotic Patients with Intermediate Hepatocellular Carcinoma: A Retrospective Analysis

Romeiro, Fernando Gomes; Sigahi, Luciana Yumi Odani; Alvarez, Matheus; Yamashiro, Fábio da Silva; Carvalho, Fabyola Barros de; Pelafsky, Leonardo; Lima, Tiago Barbalho; Franzoni, L.; Miranda, José Ricardo de Arruda; Silva, Giovanni Faria

doi:10.4236/jct.2015.63031

Cited by 1 publication

(1 citation statement)

References 15 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For now, the options after regorafenib are scarce, making the interruption of this drug even more problematic. Furthermore, combining locoregional and systemic therapies is possible for some strict indications but only sorafenib has been used with other therapies such as TACE, with conflicting results [7][8][9][10][11], thus not allowing the anticipation of results of new combinations [12].…”

Section: Discussionmentioning

confidence: 99%

How Much Time Should Be Waited and What Are the Main Findings to Evaluate the Hepatocellular Carcinoma Response to Regorafenib? A Real-Life Experience

Kawanami

Katsuda

Rocha

et al. 2021

Canadian Journal of Gastroenterology and Hepatology

Self Cite

View full text Add to dashboard Cite

Background. Hepatocellular carcinoma is a relevant cause of mortality worldwide, mainly among patients who have a prior liver disease. In spite of clear recommendations regarding surveillance and screening methods, most patients are still diagnosed only when they are no longer candidates to curative treatment modalities, while others do not achieve the goals of such treatments, thus increasing the need of anticancer drugs. Moreover, when cirrhotic patients begin to receive these drugs, many types of adverse events are seen as a reason to withdrawal, even when there are findings suggesting a good response to the treatment. Case Summary. This case report is about a cirrhotic patient who received many types of treatment, from surgery and chemoembolization during early stages to first- and second-line systemic therapy when the disease turned to be advanced. Since he had no signs of liver dysfunction and suffered tumor progression during sorafenib treatment, regorafenib was initiated. The main findings that make this case important are the adverse events after taking this second-line agent, which would certainly be considered unacceptable and would lead to the drug withdrawal. The reasons why regorafenib was maintained are explained based on clinical and imaging findings, showing how this decision led to an excellent response. Conclusions. The knowledge of the main adverse events described in the pilot clinical trials can avoid unnecessary withdrawal of regorafenib. In addition, some clinical and imaging findings can be deemed as predictors of good response to tyrosine kinase inhibitors.

show abstract

Section: Discussionmentioning

confidence: 99%

How Much Time Should Be Waited and What Are the Main Findings to Evaluate the Hepatocellular Carcinoma Response to Regorafenib? A Real-Life Experience

Kawanami

Katsuda

Rocha

et al. 2021

Canadian Journal of Gastroenterology and Hepatology

Self Cite

View full text Add to dashboard Cite

show abstract

Sorafenib after Arterial Chemoembolization in Child-Pugh A and B Cirrhotic Patients with Intermediate Hepatocellular Carcinoma: A Retrospective Analysis

Abstract: F. G. Romeiro et al. 287bined approach is cautiously performed on an individualized schedule. Our results suggest that the Child-Pugh classification should not be a limitation to this combined treatment.

Cited by 1 publication

References 15 publications

How Much Time Should Be Waited and What Are the Main Findings to Evaluate the Hepatocellular Carcinoma Response to Regorafenib? A Real-Life Experience

How Much Time Should Be Waited and What Are the Main Findings to Evaluate the Hepatocellular Carcinoma Response to Regorafenib? A Real-Life Experience

Contact Info

Product

Resources

About